**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In :	re	app	lication	of:
------	----	-----	----------	-----

Rachel E. Meyers, et al.

Application No.:

10/001,851

Group No.:

1635

Filed:

November 20, 2001

Examiner:

James Schultz

For:

47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES

**THEREOF** 

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

## IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- 1. The information disclosure statement submitted herewith is being filed:
  - (x) Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

	02	· <del>-</del>
( ) sta Of	After three months of the filing date of this nange as set forth in Section 1.491 in an internation of the action on the merits, whichever event occurrence.	ational application or the date of entry of the national onal application or after the mailing date of the first red last but <i>before</i> the mailing date of either:
	CERTIFICATION UNDER 37 C.	F.R. SECTIONS 1.8(a) and 1.10*
I hereb	y certify that, on the date shown below, this correspondent	
×	MAII deposited with the United States Postal Service in an el Commissioner for Patents, P.O. Box 1450, Alexandria. 37 C.F.R. SECTION 1.8(a)	LING envelope addressed to Mail Stop Patent Application, L, VA 22313-1450. 37 C.F.R. SECTION 1.10*
×	with sufficient postage as first class mail.	as "Express Mail Post Office to Address"  Mailing Label No
0	TRANS transmitted by facsimile to the Patent and Trademark (	MISSION Office. Sear Am
Date:	November 14, 2003	Signature Sean Hunziker (type or print name of person certifying)

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442. (Page 1 of 2)

## Practitioner's Docket No. MPI00-459P1RM (previously 10147-56U1)

<ol> <li>a final action under Section 1.113,</li> <li>a notice of allowance under Section 1.311, or</li> <li>an action that otherwise closes prosecution in the application</li> </ol>	•				
whichever occurs first.					
() Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).					
[] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).					
() No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).					
FEE PAYMENT					
2. () The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).	r				
(x) Applicant believes no fee is due in connection with this submission.					
Fee due <u>\$0.00</u>	_				
METHOD OF PAYMENT OF FEE					
3. [ ] Attached is a check in the amount of \$ [ ] Charge Account No. 501668 in the amount of \$0.00 [ ] A duplicate of this request is attached.					
If any additional fees are due, please charge Account 501668.					
MILLENNIUM PHARMACEUTICALS, INC.  By  Lean M. Silveri  Registration No. 39,030  75 Sidney Street  Cambridge, MA 02139  Telephone - 617-679-7336  Facsimile - 617-551-8820					

	1 10/02/00/1 (10 00/
Approved for us	through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U	S. DEPARTMENT OF COMMERCE
	- I'-I Old ID assistation member

Under the Paperwork Reduction Act of 1995, no persons are required to pessons to	a collection of information unless it conf	ains a valid OMB control number.
AMON OTO AMON OTO	Compl	te if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICATE TRADERS	Spplication Number Filing Date	10/001,851 November 20, 2001
CTATEMENT BY APPLICATE BADE	First Named Inventor	Rachel E. Meyers, et al
STATEMENT DI ALL LIONA	Group Art Unit	1635
handa an nagassand	Examiner Name	James Schultz
(use as many sheets as necessary)  Sheet 1 of 1	Attorney Docket Number	MPI00-459P1RM

				U.S. PATENT DOCUME	NTS	
Examiner	Cite No.1		Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Initials*	AA	6,555,669	B2	Lexicon Genetics Incorporated	04-29-2003	Entire document.
	1-25	0,000,000				
	-					
				<del> </del>		
	<u> </u>	<del> </del>		1		
	$\bot$	<b></b>		+		

				FORE	IGN PATENT DOCUM	ENTS		
Examiner Initials*	Cite No.1	Foreig	gn Patent Do		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD- YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

	Date
Examiner	Considered
Signature	00,000

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complet this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.





<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issu d the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the y ar of the r ign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.